Releaf Offers Industry First UK-Grown Medical Cannabis with Glass Pharms Partnership

Releaf, a leading medical cannabis clinic in the UK, has formed a partnership with Glass Pharms to bring the first domestically grown, THC-bearing medical cannabis flower to UK patients. This strategic collaboration aims to provide a sustainable and high-quality supply of medication, available exclusively through Releaf.

This partnership marks a significant milestone for the UK's medical cannabis industry by introducing locally-sourced cannabis cultivars. Tim Kirby, Managing Director of Releaf, emphasized the alignment of this initiative with patient needs and consistent, high-quality cannabis-based products.

Glass Pharms employs advanced AI-controlled growing conditions and laboratory facilities to ensure quality and consistency. Their cultivation process is also environmentally friendly, using 40% less power compared to traditional indoor methods.

Chloe Durrington, the first patient prescribed these cultivars, highlighted the reduced travel distance of the medication as a major benefit. Releaf's HealthTech platform, launched in February, will now feature six Releaf-branded cultivars, enhancing their unique service offering.